RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline and Talicia commercialization

• RedHill highlighted Talicia as its marketed product, co-commercialized in the U.S. with Cumberland Pharmaceuticals for adult H. pylori infection.
• FY 2025 net revenue USD 7.8 million; gross margin 74.6%; cash balance USD 4.1 million; equity financing capacity USD 31.7 million.
• Market cap about USD 5.2 million; about 5,200,000 American Depositary Shares outstanding.
• Talicia exclusivity through 2027 under FDA QIDP; U.S. patent protection until 2042; listed as a first-line option in the 2024 ACG guideline.
• Pipeline focus on late-stage GI, infectious disease, oncology programs, including opaganib, RHB-102, RHB-204, RHB-107 across Phase 2 to Phase 3-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.